2VJ Stock Overview A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ascletis Pharma Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ascletis Pharma Historical stock prices Current Share Price HK$0.36 52 Week High HK$0.37 52 Week Low HK$0.084 Beta 0.58 1 Month Change 116.77% 3 Month Change 199.17% 1 Year Change 151.39% 3 Year Change 9.70% 5 Year Change 11.73% Change since IPO -68.52%
Recent News & Updates
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
New major risk - Revenue and earnings growth Oct 14
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13 See more updates
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Nov 13
New major risk - Revenue and earnings growth Oct 14
Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F Oct 07
Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity Sep 17
Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024 Jul 30
Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024 Jun 13
Ascletis Pharma Inc., Annual General Meeting, May 23, 2024 Apr 28
Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 Apr 03
Full year 2023 earnings released: CN¥0.14 loss per share (vs CN¥0.29 loss in FY 2022) Mar 26
Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting Mar 11
Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024 Feb 24
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne Jan 24
Insufficient new directors Jan 17
New major risk - Revenue and earnings growth Jan 09
Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis Jan 02
Insufficient new directors Dec 13
Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne Dec 05
First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022) Oct 01
Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 29
Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Sep 27
Insufficient new directors Aug 31
First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022) Aug 23
Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023 Jul 24
Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis Jul 22
New minor risk - Profitability Jul 19
Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023 Jun 06
Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection May 09
Forecast breakeven date moved forward to 2023 Mar 21
Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B Feb 17
Forecast breakeven date moved forward to 2023 Feb 14
Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection Feb 01
Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa Jan 27
Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19 Jan 17
Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc Jan 03
Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19 Dec 13
Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA Dec 08
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne Dec 02
Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA Nov 30
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA Nov 24
Insufficient new directors Nov 18
Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA Nov 18
Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA Nov 16
Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022 Nov 07
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Nov 03
Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication Oct 27
Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19 Oct 11
Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash Oct 06
Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure Sep 28
Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22 Sep 16
First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021) Aug 23
Ascletis Pharma Inc. Announces Change of Company Secretary Aug 23
Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA Aug 22
Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis Aug 17
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors Aug 08
Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA Aug 05
Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients Aug 04
Ascletis Pharma Inc. to Report First Half, 2022 Results on Aug 22, 2022 Jul 28
Forecast to breakeven in 2023 Jul 07
Insufficient new directors Jul 07
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19 Jul 07
Ascletis Pharma Inc. Announces Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection Jul 05
Ascletis Pharma Inc. Announces First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection Jun 29
Ascletis Pharma Inc. Announces the Latest Phase Iib Clinical Trial Results of Subcutaneous Pd-L1 Antibody Asc22 (Envafolimab) in Patients with Chronic Hepatitis B (Chb) At an Oral Parallel Session of the International Liver Congress™ 2022 Jun 28
Ascletis Pharma Inc. Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022 Jun 16
Ascletis Pharma Inc. Appoints John P. Gargiulo as Chief Business Officer Jun 13
Ascletis Pharma Inc., Annual General Meeting, Jun 16, 2022 May 25 Ascletis Pharma Inc. Announces Approval of Investigational New Drug Application
Insufficient new directors Apr 29
Full year 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.20 loss in FY 2020) Apr 21
Ascletis Pharma Inc. Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19 Apr 20
Ascletis Pharma Inc. Receives Approval for Investigational New Drug Application by China National Medical Products Administration Apr 07
Ascletis Pharma Inc. Completes Patient Enrollment in Phase II Clinical Trial of ASC42 for Chronic Hepatitis B Indication Mar 31
Insufficient new directors Mar 30
Ascletis Pharma Inc. Announces the Latest Results of Preclinical Studies of Two Novel Anti-Cancer Drug Candidates,ASC61 and ASC60, to Be Presented At AACR Annual Meeting 2022 Mar 28
Ascletis Pharma Inc. to Report Fiscal Year 2021 Results on Mar 21, 2022 Mar 04
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Mar 01
Ascletis Pharma Inc. Provides Earnings Guidance for the Year Ended December 31, 2021 Feb 28
Ascletis Pharma Inc Announces Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients Feb 15
Ascletis Pharma Inc. Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant Feb 08
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Feb 07
Ascletis Pharma Inc. Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA Jan 27
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma Jan 24
Ascletis Pharma Inc. Announces U.S. Ind Approval of Asc22, A Subcutaneously Administered Pd-L1 Antibody for Functional Cure of Chronic Hepatitis B Jan 18
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne Jan 14
Ascletis Pharma Inc. Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication Jan 11
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors Jan 10
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F Jan 04
Ascletis Pharma Inc. Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-COV-2 Virus Jan 03
Ascletis Pharma Inc. Announces Inclusion in New Catalogue of China National Reimbursement Drug List (NRDL) of ASCLEVIR®/ GANOVO® Regimen, an All-Oral Direct Anti-Hcv Therapy Dec 03
Ascletis Pharma Inc Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRß Agonist ASC41 Sep 08
First half 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.049 loss in 1H 2020) Aug 30
Ascletis Pharma Inc. Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist Asc42 in China for Chronic Hepatitis B Indication Aug 25
Ascletis Pharma Inc.'s artner Sagimet Dosed First Patient in FASCINATE-2 Phase IIb Trial in NASH Patients with Moderate to Advanced Fibrosis Aug 17
Ascletis Pharma Inc. Announces China NMPA Approves Phase II Clinical Trial of Asc40 for the Treatment of Patients with Acne Aug 09 Shareholder Returns 2VJ DE Biotechs DE Market 7D 33.1% 1.2% -0.3% 1Y 151.4% -14.3% 7.0%
See full shareholder returns
Return vs Market: 2VJ exceeded the German Market which returned 7% over the past year.
Price Volatility Is 2VJ's price volatile compared to industry and market? 2VJ volatility 2VJ Average Weekly Movement 17.6% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2VJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2VJ's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Show more Ascletis Pharma Inc. Fundamentals Summary How do Ascletis Pharma's earnings and revenue compare to its market cap? 2VJ fundamental statistics Market cap €373.56m Earnings (TTM ) -€34.03m Revenue (TTM ) €1.33m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2VJ income statement (TTM ) Revenue CN¥10.09m Cost of Revenue CN¥22.72m Gross Profit -CN¥12.63m Other Expenses CN¥245.84m Earnings -CN¥258.47m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.27 Gross Margin -125.17% Net Profit Margin -2,561.68% Debt/Equity Ratio 0%
How did 2VJ perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 12:36 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ascletis Pharma Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ling Zhang China Merchants Securities (HK) Co., Ltd Mingrui Wang Everbright Securities Co. Ltd. Siao Ye Everbright Securities Co. Ltd.
Show 4 more analysts 
